Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 1/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15124013 | 1.00 | CYP2E1 (0.77) | CYP2E1NR1I2EPHX2GAATSHR | |
| SCHEMBL10265151 | 0.91 | CYP2E1 (0.64) | CYP2E1NR1I2EPHX2GAATSHR | |
| SCHEMBL319216 | 0.91 | CYP2E1 (0.64) | CYP2E1NR1I2EPHX2GAATSHR | |
| SCHEMBL327723 | 0.91 | CYP2E1 (0.80) | CYP2E1NR1I2EPHX2 | |
| SCHEMBL327724 | 0.91 | CYP2E1 (0.80) | CYP2E1NR1I2EPHX2 | |
| SCHEMBL15130716 | 0.90 | CYP2E1 (0.79) | CYP2E1NR1I2EPHX2 | |
| SCHEMBL318909 | 0.87 | CYP2E1 (0.80) | CYP2E1NR1I2EPHX2 | |
| SCHEMBL318910 | 0.87 | CYP2E1 (0.80) | CYP2E1NR1I2EPHX2 | |
| SCHEMBL318357 | 0.87 | CYP2E1 (0.79) | CYP2E1NR1I2EPHX2 | |
| SCHEMBL318358 | 0.87 | CYP2E1 (0.79) | CYP2E1NR1I2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190289-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-25 | — | — | US | disclosed |
| EP-2585447-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2013-05-01 | — | — | EP | disclosed |
| WO-2012006055-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190289-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | SLC10A1, ACE, CEL | CYP2E1 1027/4885NR1I2 1500/4885EPHX2 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.